查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088599

組織工程皮膚替代市場：按產品類型、材料、細胞組成、應用和最終用戶分類－2026-2032年全球市場預測

Tissue Engineered Skin Substitutes Market by Product Type, Material, Cellular Composition, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基於組織工程的皮膚替代市場將成長至 34.6 億美元，複合年成長率為 13.51%。

主要市場統計數據
基準年 2025 14.2億美元
預計年份：2026年 16.1億美元
預測年份 2032 34.6億美元
複合年成長率 (%) 13.51%

基於組織工程的皮膚替代物是先進的傷口縫合護理和創傷護理，旨在促進燒燙傷、糖尿病足潰瘍、下肢靜脈潰瘍、手術傷口和創傷的傷口癒合、組織再生和功能恢復。此類別包括細胞和非細胞基質、層級構造生物結構、膠原蛋白蛋白支架、真皮再生模板、羊膜衍生產品以及生物工程表皮或真皮替代物。

這項需求得到了充分的臨床驗證。根據世界衛生組織（WHO）估計，燒燙傷每年導致約18萬人死亡，主要集中在中低收入國家。國際糖尿病聯盟（IDF）估計，2021年全球有5.37億成年人患有糖尿病，這群人罹患糖尿病足潰瘍和創傷治療癒合延遲的風險較高。同時，人口老化、外科手術數量的增加以及臨床治療中對保肢治療的重視，都使得組織工程皮膚替代物在醫院、創傷護理中心、燒傷治療科和門診等場所的重要性日益凸顯。

組織工程在皮膚替代品領域帶來的變革

基於組織工程的皮膚替代物領域正從被動傷口覆蓋轉向生物活性再生。臨床醫生擴大根據傷口準備、血管生成支持、感染控制、操作特性、耐久性、傷口縫合時間以及來自隨機臨床試驗和真實世界臨床結果的證據等標準來評估產品。

人工智慧對皮膚替代品的累積影響

人工智慧（AI）正成為組織工程皮膚替代物整個價值鏈中一股切實的驅動力。在研發階段，機器學習可用於分析生物材料、細胞行為、支架結構和創傷治療生物標記物，從而加速候選材料的篩選並改善結構設計。在生產製造階段，人工智慧驅動的影像分析和製程監控可以支援與細胞活力、基質均勻性、無菌性和批間重複性相關的品管。

全球皮膚替代品市場的關鍵區域洞察

由於亞太地區擁有龐大的病患群體，加之中國、印度、日本、韓國和澳洲等國再生醫學、生物材料和醫院基礎設施的快速發展，該地區的戰略重要性日益凸顯。糖尿病負擔沉重、燒燙傷發生率高，以及大眾對先進療法的關注，都支撐著對組織工程皮膚替代品的長期需求。然而，各國在保險覆蓋範圍、專家資源和先進創傷護理服務方面仍存在差異。

關於利用組織工程技術引入皮膚替代品的關鍵群體特定見解。

東協市場的特點是醫院投資增加、糖尿病盛行率上升以及先進創傷護理服務取得不均，這為經濟高效的組織工程皮膚替代品、臨床培訓和標準化創傷護理方案創造了機會。海灣合作理事會（GCC）國家受益於高額的醫療費用支出、參與醫療旅遊的意願以及對專科醫院的投資，這些因素在臨床和經濟證據的支持下，將促進高品質創傷護理技術的應用。

各國對透過組織工程技術開發的皮膚替代品的深入了解

美國是商業性最具影響力的國家，這得益於其龐大的慢性傷口患者群體、專業的創傷護理中心、FDA的監管以及聯邦醫療保險（Medicare）報銷在推廣先進創傷護理方面發揮的核心作用。加拿大強調在公共醫療保健體系中採用循證醫學方法，而墨西哥和巴西則面臨著與糖尿病、創傷、燒燙傷和外科上的照護相關的日益成長的需求，其可負擔性、醫院採購和當地醫療資源獲取情況都會影響先進傷口護理的推廣進程。

為行業領導者提供的實用建議

產業領導者應優先考慮具有差異化作用機制、可重複生產流程以及與傷口縫合、植皮成活、感染減少、疼痛緩解、住院時間縮短、截肢避免和生活品質 (QOL) 相關的臨床數據的產品。證據產生應盡可能包括隨機對照試驗、來自真實世界臨床實踐的可操作證據、註冊登記數據以及與支付方決策相關的衛生經濟學分析。

調查方法

本執行摘要基於系統的二手研究方法，利用公開可獲取和可驗證的來源，包括監管文件、同行檢驗的臨床文獻、公共衛生研究途徑、產品資訊來源、報銷指南以及世界衛生組織 (WHO) 和國際糖尿病聯盟 (IDF) 等認可的衛生組織。

結論

基於組織工程的皮膚替代品正從一種小眾的傷口敷料產品轉變為實證再生醫學領域的一類產品。最大的機會出現在慢性傷口負擔、燒傷護理需求、臨床基礎設施、監管政策清晰度和醫保報銷支援等方面相互交織的領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：基於組織工程的皮膚替代市場：按產品類型分類

  • 複合材料置換
  • 真皮替代材料
    • 生物合成
    • 自然的
      • 膠原蛋白
      • 纖維蛋白
      • 玻尿酸
    • 合成
      • PLGA
      • 聚己內酯
      • 聚氨酯
  • 表皮替代材料

第8章：基於組織工程的皮膚替代市場：依材料分類

  • 生物合成
  • 天然材質
    • 膠原蛋白
    • 纖維蛋白
    • 玻尿酸
  • 合成
    • PLGA
    • 聚己內酯
    • 聚氨酯

第9章：基於組織工程的皮膚替代市場：按細胞組成分類

  • 無細胞型
  • 自體培養
  • 不同起源
    • 牛
    • 豬

第10章：基於組織工程的皮膚替代市場：按應用領域分類

  • 急性創傷護理
  • 燒燙傷治療
  • 慢性創傷護理
    • 糖尿病足潰瘍
    • 壓瘡
    • 下肢靜脈潰瘍
  • 化妝品和美容

第11章：基於組織工程的皮膚替代市場：按最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

第12章：基於組織工程的皮膚替代市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：以組織工程為基礎的皮膚替代市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：基於組織工程的皮膚替代市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Acelity LP Inc.
  • AlloSource, Inc.
  • Amarantus BioScience Holdings, Inc.
  • Amnio Technology, LLC
  • Amniox Medical, Inc.
  • Anika Therapeutics, Inc.
  • Avita Medical, Inc.
  • B. Braun Melsungen AG
  • Coloplast A/S
  • ConvaTec Group Plc
  • Gunze Limited
  • Integra LifeSciences Holdings Corporation
  • Organogenesis Holdings Inc.
  • PolarityTE, Inc.
  • PolyNovo Limited
  • Promethean LifeSciences, Inc.
  • Regenicin, Inc.
  • RTI Surgical Holdings, Inc.
  • Smith & Nephew plc
  • Stratatech Corporation
  • Stryker Corporation
  • Tissue Regenix Group plc
  • Vericel Corporation
Product Code: MRR-0360AB17E196

The Tissue Engineered Skin Substitutes Market is projected to grow by USD 3.46 billion at a CAGR of 13.51% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.42 billion
Estimated Year [2026] USD 1.61 billion
Forecast Year [2032] USD 3.46 billion
CAGR (%) 13.51%

Tissue engineered skin substitutes are advanced wound care and regenerative medicine products designed to support wound closure, tissue regeneration, and functional recovery in burns, diabetic foot ulcers, venous leg ulcers, surgical wounds, and traumatic injuries. The category includes cellular and acellular matrices, bilayered living constructs, collagen-based scaffolds, dermal regeneration templates, amniotic membrane-derived products, and bioengineered epidermal or dermal equivalents.

Demand is supported by well-documented clinical need. The World Health Organization reports that burns cause an estimated 180,000 deaths each year, primarily in low- and middle-income countries. The International Diabetes Federation estimated that 537 million adults were living with diabetes in 2021, a population at elevated risk of diabetic foot ulcers and delayed wound healing. In parallel, population aging, higher surgical volumes, and the clinical shift toward limb preservation are increasing the relevance of tissue engineered skin substitutes across hospitals, wound care centers, burn units, and outpatient care settings.

Transformative Shifts in the Tissue Engineered Skin Landscape

The tissue engineered skin substitutes landscape is shifting from passive wound coverage toward biologically active regeneration. Clinicians are increasingly evaluating products based on wound-bed preparation, vascularization support, infection control, handling characteristics, durability, time to closure, and evidence from randomized clinical trials or real-world outcomes.

Regulatory scrutiny and reimbursement discipline are also reshaping adoption. In the United States, the FDA classifies many skin substitute products under biologics, devices, or combination-product pathways, while Medicare coverage decisions increasingly emphasize appropriate use, documentation, and medical necessity. In Europe, the Medical Device Regulation has raised evidence and post-market surveillance expectations. These changes favor manufacturers with strong clinical data, quality systems, scalable manufacturing, and clear health-economic value.

Cumulative Impact of Artificial Intelligence on Skin Substitutes

Artificial intelligence is becoming a practical enabler across the tissue engineered skin substitutes value chain. In research and development, machine learning can help analyze biomaterials, cell behavior, scaffold architecture, and wound-healing biomarkers to accelerate candidate selection and improve construct design. In manufacturing, AI-enabled image analysis and process monitoring can support quality control for cell viability, matrix consistency, sterility assurance, and batch-to-batch reproducibility.

AI also strengthens clinical adoption. Digital wound measurement tools, computer vision, and predictive analytics can help clinicians assess wound area, tissue composition, infection risk, and healing trajectory. These capabilities are particularly relevant for diabetic foot ulcers and venous leg ulcers, where objective measurement and earlier intervention can improve care pathways. The most defensible AI applications will be those validated against clinical outcomes, integrated into clinical workflow, and aligned with privacy, cybersecurity, and medical-device regulatory requirements.

Key Regional Insights Across Global Skin Substitute Markets

Asia-Pacific is gaining strategic importance because China, India, Japan, South Korea, and Australia combine large patient populations with expanding regenerative medicine, biomaterials, and hospital infrastructure. Diabetes burden, burn incidence, and public-sector interest in advanced therapies support long-term demand for tissue engineered skin substitutes, although reimbursement coverage, specialist availability, and access to advanced wound care remain uneven across countries.

North America remains a leading commercial and clinical evidence hub, supported by established wound care networks, burn centers, FDA-regulated product pathways, and comparatively mature reimbursement systems. Europe benefits from strong research institutions, advanced therapy expertise, and structured health technology assessment, while the EU Medical Device Regulation is increasing the importance of clinical evidence and post-market performance data. Latin America shows rising need in Brazil and Mexico, particularly for diabetes-related wounds, trauma, and surgical care, but procurement budgets and specialist access influence adoption. The Middle East, led by GCC health system investments, is expanding advanced wound care capacity, while Africa has substantial burn, trauma, and infection-related wound needs but faces affordability, distribution, trained workforce, and infrastructure constraints.

Key Group Insights for Tissue Engineered Skin Substitute Adoption

ASEAN markets are characterized by growing hospital investment, rising diabetes prevalence, and uneven access to advanced wound care, creating opportunities for cost-effective tissue engineered skin substitutes, clinical training, and standardized wound care protocols. The GCC benefits from high healthcare spending, medical tourism ambitions, and investments in specialty hospitals, which support adoption of premium wound care technologies when supported by clinical and economic evidence.

The European Union is shaped by harmonized regulatory expectations under MDR, strong academic research, and payer emphasis on value, safety, and post-market performance. BRICS countries combine significant patient volumes with expanding domestic biotechnology and medical device capabilities, but pricing, reimbursement, import policy, and local manufacturing requirements can influence market entry. G7 markets generally offer stronger clinical infrastructure, regulatory clarity, and reimbursement pathways, while NATO countries overlap with many high-income health systems where trauma preparedness, burn care capacity, and resilient medical supply chains are increasingly relevant.

Key Country Insights in Tissue Engineered Skin Substitutes

The United States is the most commercially influential country because of its large chronic wound population, specialized wound care centers, FDA oversight, and the central role of Medicare reimbursement in advanced wound care adoption. Canada emphasizes evidence-based adoption within publicly funded care, while Mexico and Brazil present growing needs linked to diabetes, trauma, burns, and surgical care, with affordability, hospital procurement, and regional access shaping uptake.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have advanced clinical expertise and established wound care pathways, while Germany and France are particularly important for medical technology evaluation, reimbursement discipline, and clinical evidence expectations. Russia has clinical demand in burns and trauma care but faces procurement and supply-chain complexity. China and India offer large patient pools and expanding regenerative medicine capacity, Japan and South Korea contribute strong biomaterials, cell therapy, and advanced manufacturing capabilities, and Australia combines advanced burn care, clinical research, and structured reimbursement evaluation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize products with differentiated mechanisms of action, reproducible manufacturing, and clinical data tied to wound closure, graft take, infection reduction, pain, length of stay, amputation avoidance, and quality of life. Evidence generation should include randomized studies where feasible, pragmatic real-world evidence, registry data, and health-economic analyses relevant to payer decision-making.

Commercial strategy should be region-specific. Organizations should align regulatory classification early, build reimbursement dossiers before launch, train clinicians on patient selection and application protocols, and develop partnerships with burn centers, diabetic foot clinics, and wound care networks. Leaders should also invest in supply-chain resilience, cold-chain or shelf-stable formats where appropriate, and AI-enabled wound documentation tools that support clinical consistency, traceability, and reimbursement compliance.

Research Methodology

This executive summary is based on a structured secondary research approach using publicly available and verifiable sources, including regulatory agency materials, peer-reviewed clinical literature, public health datasets, product labels, reimbursement guidance, and recognized health organizations such as the World Health Organization and the International Diabetes Federation.

The methodology emphasizes triangulation across clinical need, regulatory pathways, product evidence, healthcare delivery models, and regional adoption factors. Insights are interpreted through a market intelligence framework that evaluates demand drivers, technology maturity, competitive positioning, reimbursement dynamics, and implementation barriers without relying on unverified claims, market sizing, market share estimates, or unsupported projections.

Conclusion

Tissue engineered skin substitutes are moving from niche wound coverage products toward an evidence-driven regenerative medicine category. The strongest opportunities are emerging where chronic wound burden, burn care needs, clinical infrastructure, regulatory clarity, and reimbursement support converge.

Future leadership will depend on credible clinical outcomes, scalable quality-controlled manufacturing, regulatory readiness, and demonstrable economic value. Organizations that integrate biomaterials science, cell biology, digital wound intelligence, and payer-focused evidence will be best positioned to advance patient outcomes and support sustainable growth in the global tissue engineered skin substitutes market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tissue Engineered Skin Substitutes Market, by Product Type

  • 7.1. Composite Substitute
  • 7.2. Dermal Substitute
    • 7.2.1. Biosynthetic
    • 7.2.2. Natural
      • 7.2.2.1. Collagen
      • 7.2.2.2. Fibrin
      • 7.2.2.3. Hyaluronic Acid
    • 7.2.3. Synthetic
      • 7.2.3.1. PLGA
      • 7.2.3.2. Polycaprolactone
      • 7.2.3.3. Polyurethane
  • 7.3. Epidermal Substitute

8. Tissue Engineered Skin Substitutes Market, by Material

  • 8.1. Biosynthetic
  • 8.2. Natural
    • 8.2.1. Collagen
    • 8.2.2. Fibrin
    • 8.2.3. Hyaluronic Acid
  • 8.3. Synthetic
    • 8.3.1. PLGA
    • 8.3.2. Polycaprolactone
    • 8.3.3. Polyurethane

9. Tissue Engineered Skin Substitutes Market, by Cellular Composition

  • 9.1. Acellular
  • 9.2. Cultured Autologous
  • 9.3. Xenogeneic
    • 9.3.1. Bovine
    • 9.3.2. Porcine

10. Tissue Engineered Skin Substitutes Market, by Application

  • 10.1. Acute Wound Care
  • 10.2. Burn Treatment
  • 10.3. Chronic Wound Care
    • 10.3.1. Diabetic Foot Ulcer
    • 10.3.2. Pressure Ulcer
    • 10.3.3. Venous Leg Ulcer
  • 10.4. Cosmetic And Aesthetic

11. Tissue Engineered Skin Substitutes Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Tissue Engineered Skin Substitutes Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Tissue Engineered Skin Substitutes Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tissue Engineered Skin Substitutes Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Acelity L.P. Inc.
  • 16.2. AlloSource, Inc.
  • 16.3. Amarantus BioScience Holdings, Inc.
  • 16.4. Amnio Technology, LLC
  • 16.5. Amniox Medical, Inc.
  • 16.6. Anika Therapeutics, Inc.
  • 16.7. Avita Medical, Inc.
  • 16.8. B. Braun Melsungen AG
  • 16.9. Coloplast A/S
  • 16.10. ConvaTec Group Plc
  • 16.11. Gunze Limited
  • 16.12. Integra LifeSciences Holdings Corporation
  • 16.13. Organogenesis Holdings Inc.
  • 16.14. PolarityTE, Inc.
  • 16.15. PolyNovo Limited
  • 16.16. Promethean LifeSciences, Inc.
  • 16.17. Regenicin, Inc.
  • 16.18. RTI Surgical Holdings, Inc.
  • 16.19. Smith & Nephew plc
  • 16.20. Stratatech Corporation
  • 16.21. Stryker Corporation
  • 16.22. Tissue Regenix Group plc
  • 16.23. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPOSITE SUBSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPOSITE SUBSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOSITE SUBSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DERMAL SUBSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DERMAL SUBSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DERMAL SUBSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOSYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOSYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOSYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLLAGEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLLAGEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLLAGEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIBRIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIBRIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FIBRIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYALURONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYALURONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYALURONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLGA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLGA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLGA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYURETHANE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYURETHANE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYURETHANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EPIDERMAL SUBSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EPIDERMAL SUBSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EPIDERMAL SUBSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOSYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOSYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOSYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NATURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLLAGEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLLAGEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLLAGEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIBRIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBRIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIBRIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYALURONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYALURONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYALURONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLGA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLGA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLGA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POLYCAPROLACTONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POLYURETHANE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POLYURETHANE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POLYURETHANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACELLULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACELLULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACELLULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CULTURED AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CULTURED AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CULTURED AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL XENOGENEIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL XENOGENEIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL XENOGENEIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PORCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PORCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PORCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE WOUND CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE WOUND CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE WOUND CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BURN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BURN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BURN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC WOUND CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC WOUND CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC WOUND CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRESSURE ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRESSURE ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PRESSURE ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VENOUS LEG ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VENOUS LEG ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VENOUS LEG ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COSMETIC AND AESTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COSMETIC AND AESTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COSMETIC AND AESTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 216. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 219. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 221. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 255. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 256. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 258. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 260. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 268. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 270. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 271. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 273. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CELLULAR COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY XENOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUND CARE, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DERMAL SUBSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE